Tatsis Ourania

SEC source: 0000875320-26-000253 · wk-form4_1784837739.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,572

F1 · shares: Restricted stock unit award that vests on 03/31/2030.

SEC source: 0000875320-26-000245 · wk-form4_1783455338.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,321

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

SEC source: 0001193125-26-217588 · ownership.xml · derivative · entry 1

Tatsis Ourania · CIK 0001789815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,393

Underlying: Common Stock · 27,393 shares

Expires 2036-05-06

F1 · derivative.exercise_date: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000875320-26-000120 · wk-form4_1772150109.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,763

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

SEC source: 0000875320-26-000120 · wk-form4_1772150109.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,023

SEC source: 0000875320-26-000098 · wk-form4_1771536504.xml · nonDerivative · entry 4

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,650

F2 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

SEC source: 0000875320-26-000098 · wk-form4_1771536504.xml · nonDerivative · entry 3

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,018

F2 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

SEC source: 0000875320-26-000098 · wk-form4_1771536504.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,627

SEC source: 0000875320-26-000098 · wk-form4_1771536504.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,921

F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027.

SEC source: 0000875320-26-000076 · wk-form4_1771451036.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,132

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $499.99 (range $499.99 to $500.04).

F3 · price: Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

SEC source: 0000875320-26-000076 · wk-form4_1771451036.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,632

SEC source: 0000875320-26-000052 · wk-form4_1770934130.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,436

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

SEC source: 0000875320-26-000052 · wk-form4_1770934130.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,902

SEC source: 0000875320-26-000026 · wk-form4_1769463422.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,042

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

SEC source: 0000875320-26-000026 · wk-form4_1769463422.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,159

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

SEC source: 0000875320-26-000004 · wk-form4_1767992722.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,293

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

SEC source: 0000875320-25-000244 · wk-form4_1764969166.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,793

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

F2 · balance_after: Open market sales reported on this line occurred at a weighted average price of $449.99 (range $449.99 to $450.00).

F3 · balance_after: Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-099252 · ownership.xml · derivative · entry 2

Tatsis Ourania · CIK 0001789815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,200 shares

Expires not disclosed

F1 · price: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

F2 · price: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

F1 · derivative.exercise_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

F2 · derivative.exercise_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

F1 · derivative.expiration_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

F2 · derivative.expiration_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099252 · ownership.xml · derivative · entry 1

Tatsis Ourania · CIK 0001789815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 267,541 shares

Expires not disclosed

F1 · price: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

F2 · price: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

F1 · derivative.exercise_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

F2 · derivative.exercise_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

F1 · derivative.expiration_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the

F2 · derivative.expiration_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-083227 · ownership.xml · derivative · entry 1

Tatsis Ourania · CIK 0001789815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,200

Underlying: Common Stock · 42,200 shares

Expires 2035-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.

SEC source: 0000875320-25-000146 · wk-form4_1741810227.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,239

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 11/22/2024.

SEC source: 0000875320-25-000141 · wk-form4_1741295323.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,481

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 11/22/2024.

SEC source: 0000875320-25-000135 · wk-form4_1740779311.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,539

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

SEC source: 0000875320-25-000135 · wk-form4_1740779311.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,069

SEC source: 0000875320-25-000115 · wk-form4_1740604500.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,031

F1 · kind: Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

SEC source: 0000875320-25-000115 · wk-form4_1740604500.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,385

SEC source: 0000875320-25-000095 · wk-form4_1740000996.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,695

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

SEC source: 0000875320-25-000095 · wk-form4_1740000996.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,939

SEC source: 0000875320-25-000073 · wk-form4_1739567930.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,232

F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026.

SEC source: 0000875320-25-000048 · wk-form4_1739397030.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,021

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

SEC source: 0000875320-25-000048 · wk-form4_1739397030.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,331

SEC source: 0000875320-25-000024 · wk-form4_1738878214.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,474

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

SEC source: 0000875320-25-000024 · wk-form4_1738878214.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,360

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.

SEC source: 0000950170-24-078782 · ownership.xml · derivative · entry 1

Tatsis Ourania · CIK 0001789815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,541

Underlying: Common Stock · 267,541 shares

Expires 2034-06-25

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date of the option is the grant date. The shares of common stock underlying the option are scheduled to vest in equal monthly installments through June 26, 2027, subject to the Reporting Person's continued service as a director.

SEC source: 0000875320-24-000168 · wk-form4_1717618128.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,098

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

SEC source: 0000875320-24-000166 · wk-form4_1717445345.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,273

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

SEC source: 0000875320-24-000166 · wk-form4_1717445345.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,523

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

SEC source: 0000875320-24-000109 · wk-form4_1709071355.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,804

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000875320-24-000109 · wk-form4_1709071355.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,158

SEC source: 0000875320-24-000093 · wk-form4_1708723675.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,467

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000875320-24-000080 · wk-form4_1708551763.xml · nonDerivative · entry 3

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,827

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000875320-24-000080 · wk-form4_1708551763.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,307

SEC source: 0000875320-24-000080 · wk-form4_1708551763.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,680

SEC source: 0000875320-24-000055 · wk-form4_1707862996.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,179

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000875320-24-000055 · wk-form4_1707862996.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,493

SEC source: 0000875320-24-000032 · wk-form4_1707428720.xml · nonDerivative · entry 3

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,593

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025.

SEC source: 0000875320-24-000032 · wk-form4_1707428720.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,479

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.

SEC source: 0000875320-24-000032 · wk-form4_1707428720.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,613

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.

SEC source: 0001209191-23-047309 · doc4.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,637

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000899243-23-018112 · doc4.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,137

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.